NASDAQ:BPMC
Blueprint Medicines Corporation Stock News
$102.71
-0.92 (-0.89%)
At Close: May 22, 2024
Xilio Therapeutics Appoints Daniel S. Lynch as Chair of Board of Directors
12:00am, Wednesday, 17'th Jun 2020
Xilio Therapeutics, a company developing potent, tumor-selective immunotherapies for patients with cancer, today announced that Daniel S. Lynch has be
The Shareholder of BELLUS Health (NASDAQ: BLU) is Selling Shares - Markets
11:18pm, Tuesday, 16'th Jun 2020
Today, the Shareholder of BELLUS Health (BLU – Research Report), Tavistock Life Sciences, sold shares of BLU for $17.09M. This
The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage
12:00am, Sunday, 07'th Jun 2020
The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs.
Negative clinical readouts led to some strong selling in...
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced updated clinical data from p
Blueprint Medicines (BPMC) Up 15.5% Since Last Earnings Report: Can It Continue?
03:32pm, Friday, 05'th Jun 2020
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12:00pm, Wednesday, 03'rd Jun 2020
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on June 1, 2
The Debate Is Over: This Cancer Stock Is Winning the GIST Race
11:11am, Wednesday, 03'rd Jun 2020
Blueprint Medicines and Deciphera Pharmaceuticals were going toe-to-toe developing treatments for this rare cancer. Investors can now call the winner.
Hedge Funds Are Done Buying Blueprint Medicines Corporation (BPMC)
07:05am, Wednesday, 03'rd Jun 2020
In this article we will take a look at whether hedge funds think Blueprint Medicines Corporation (NASDAQ:BPMC) is a good investment right now. We check hedge fund and billionaire investor sentiment be
Hedge Funds Are Done Buying Blueprint Medicines Corporation (BPMC)
01:49pm, Tuesday, 02'nd Jun 2020
In this article we will take a look at whether hedge funds think Blueprint Medicines Corporation (NASDAQ:BPMC) is a good investment right now. We check hedge fund and billionaire investor sentiment be
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
12:00am, Monday, 01'st Jun 2020
Despite the FDA tied up with COVID-19-related activities, May turned out to be a positive month for biopharma companies from the perspective of drug approvals. Three new molecular...
8 Stocks Viking Global Investors Continues to Buy
05:13pm, Friday, 29'th May 2020
Visa and Cigna make the list Continue reading...
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced data from the ongoing ARROW
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
12:00am, Friday, 29'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 28)
ADC Therapeutics SA (NYSE:...
Blueprint Medicines to Present at Upcoming Investors Conferences
08:30pm, Wednesday, 27'th May 2020
Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation in the foll
Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live conf
